97 related articles for article (PubMed ID: 26762970)
1. The tyrosine kinase inhibitor toceranib in feline injection site sarcoma: efficacy and side effects.
Holtermann N; Kiupel M; Hirschberger J
Vet Comp Oncol; 2017 Jun; 15(2):632-640. PubMed ID: 26762970
[TBL] [Abstract][Full Text] [Related]
2. Feline Injection-Site Sarcoma and Other Adverse Reactions to Vaccination in Cats.
Hartmann K; Egberink H; Möstl K; Addie DD; Belák S; Boucraut-Baralon C; Frymus T; Lloret A; Hofmann-Lehmann R; Marsilio F; Pennisi MG; Tasker S; Thiry E; Truyen U; Hosie MJ
Viruses; 2023 Aug; 15(8):. PubMed ID: 37632050
[TBL] [Abstract][Full Text] [Related]
3. Retrospective evaluation of toceranib phosphate (Palladia) use in the treatment of feline pancreatic carcinoma.
Rosario CO; Musser ML; Yuan L; Mochel JP; Talbott J; Johannes CM; Berger EP
Can Vet J; 2023 Dec; 64(12):1143-1148. PubMed ID: 38046430
[TBL] [Abstract][Full Text] [Related]
4. A Scoping Review on Tyrosine Kinase Inhibitors in Cats: Current Evidence and Future Directions.
Žagar Ž; Schmidt JM
Animals (Basel); 2023 Sep; 13(19):. PubMed ID: 37835664
[TBL] [Abstract][Full Text] [Related]
5. Low dose meloxicam is safe and tolerable when combined with toceranib phosphate in cancer-bearing cats.
Keepman SJ; Pellin MA
J Feline Med Surg; 2022 Dec; 24(12):1187-1194. PubMed ID: 34923878
[TBL] [Abstract][Full Text] [Related]
6. Feline maxillary sarcoma: clinicopathologic features of spindle cell sarcomas from the maxilla of 25 cats.
Harvey A; Soukup JW; Bell CM
J Feline Med Surg; 2022 Dec; 24(12):e647-e654. PubMed ID: 36350718
[TBL] [Abstract][Full Text] [Related]
7. Toceranib phosphate and firocoxib-mediated partial response in a dog with advanced intranasal sarcoma.
Osada H; Okazawa T; Kushida K; Kishimoto M; Ikeda M; Kondo H; Kimura J; Ohmori K
J Vet Med Sci; 2023 Sep; 85(9):1004-1009. PubMed ID: 37532540
[TBL] [Abstract][Full Text] [Related]
8. Origins of injection-site sarcomas in cats: the possible role of chronic inflammation-a review.
Woodward KN
ISRN Vet Sci; 2011; 2011():210982. PubMed ID: 23738095
[TBL] [Abstract][Full Text] [Related]
9. Toxicity and response in cats with neoplasia treated with toceranib phosphate.
Harper A; Blackwood L
J Feline Med Surg; 2017 Jun; 19(6):619-623. PubMed ID: 27090289
[TBL] [Abstract][Full Text] [Related]
10. Tolerability of toceranib phosphate (Palladia) when used in conjunction with other therapies in 35 cats with feline oral squamous cell carcinoma: 2009-2013.
Olmsted GA; Farrelly J; Post GS; Smith J
J Feline Med Surg; 2017 Jun; 19(6):568-575. PubMed ID: 26951557
[TBL] [Abstract][Full Text] [Related]
11. Retrospective evaluation of toceranib phosphate (Palladia®) toxicity in cats.
Merrick CH; Pierro J; Schleis SE; Sones EA; Wright ZM; Regan RC; Siedlecki CT; Bergman PJ
Vet Comp Oncol; 2017 Sep; 15(3):710-717. PubMed ID: 27041701
[TBL] [Abstract][Full Text] [Related]
12. Quantification of surgical margin length changes after excision of feline injection site sarcomas-A pilot study.
Terry JL; Milovancev M; Nemanic S; Löhr CV
Vet Surg; 2017 Feb; 46(2):189-196. PubMed ID: 27990649
[TBL] [Abstract][Full Text] [Related]
13. Feline Injection-Site Sarcoma.
Porcellato I; Menchetti L; Brachelente C; Sforna M; Reginato A; Lepri E; Mechelli L
Vet Pathol; 2017 Mar; 54(2):204-211. PubMed ID: 28005492
[TBL] [Abstract][Full Text] [Related]
14. Doxorubicin Conjugated to Glutathione Stabilized Gold Nanoparticles (Au-GSH-Dox) as an Effective Therapeutic Agent for Feline Injection-Site Sarcomas-Chick Embryo Chorioallantoic Membrane Study.
Zabielska-Koczywąs K; Dolka I; Król M; Żbikowski A; Lewandowski W; Mieczkowski J; Wójcik M; Lechowski R
Molecules; 2017 Feb; 22(2):. PubMed ID: 28208720
[TBL] [Abstract][Full Text] [Related]
15. Prospective evaluation of toceranib phosphate in metastatic canine osteosarcoma.
Laver T; London CA; Vail DM; Biller BJ; Coy J; Thamm DH
Vet Comp Oncol; 2018 Mar; 16(1):E23-E29. PubMed ID: 28621057
[TBL] [Abstract][Full Text] [Related]
16. Changes in the dimension and volume of feline injection-site sarcomas following formalin fixation as determined by use of the ellipsoid volume formula and three-dimensional computed tomography software.
Terry JL; Milovancev M; Löhr CV; Nemanic S
Am J Vet Res; 2016 Jun; 77(6):620-6. PubMed ID: 27227500
[TBL] [Abstract][Full Text] [Related]
17. Safety evaluation of combination doxorubicin and toceranib phosphate (Palladia®) in tumour bearing dogs: a phase I dose-finding study.
Pellin MA; Wouda RM; Robinson K; Tsimbas K; Kurzman ID; Biller BJ; Vail DM
Vet Comp Oncol; 2017 Sep; 15(3):919-931. PubMed ID: 27146577
[TBL] [Abstract][Full Text] [Related]
18. Anti-proliferative effect of metformin on a feline injection site sarcoma cell line independent of Mtor inhibition.
Pierro J; Saba C; McLean K; Williams R; Karpuzoglu E; Prater R; Hoover K; Gogal R
Res Vet Sci; 2017 Oct; 114():74-79. PubMed ID: 28319830
[TBL] [Abstract][Full Text] [Related]
19. Epirubicin in the treatment of canine histiocytic sarcoma: sequential, alternating and rescue chemotherapy.
Mason SL; Finotello R; Blackwood L
Vet Comp Oncol; 2018 Mar; 16(1):E30-E37. PubMed ID: 28621004
[TBL] [Abstract][Full Text] [Related]
20. Effects of toceranib phosphate (Palladia) monotherapy on multidrug resistant lymphoma in dogs.
Yamazaki H; Miura N; Lai YC; Takahashi M; Goto-Koshino Y; Yasuyuki M; Nakaichi M; Tsujimoto H; Setoguchi A; Endo Y
J Vet Med Sci; 2017 Jul; 79(7):1225-1229. PubMed ID: 28592719
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
